Hercules Capital (HTGC) delivered earnings and revenue surprises of 0% and 1.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Yelp (YELP) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

While the top- and bottom-line numbers for Bright Horizons (BFAM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

While the top- and bottom-line numbers for Coinbase Global (COIN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Although the revenue and EPS for Kinsale Capital Group (KNSL) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

While the top- and bottom-line numbers for Twilio (TWLO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024.

This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024.

NEW YORK, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product Ryoncil® ( remestemcel-L ) is being highlighted at the 2025 Transplantation & ...

NEW YORK, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited MESOMSB ) , a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product Ryoncil® ( remestemcel-L ) is being highlighted at the 2025 Transplantation & Cellular ...